Evidence map›Paper›PMID 26091081›Full record

ArticleHuman vaccines & immunotherapeutics2015

Tandem truncated rotavirus VP8* subunit protein with T cell epitope as non-replicating parenteral vaccine is highly immunogenic.

Xiaobo Wen, Dianjun Cao, Ronald W Jones, Yasutaka Hoshino, Lijuan Yuan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaobo Wena College of Animal Science & Veterinary Medicine; Heilongjiang Bayi Agricultural University ; Daqing , Heilongjiang Province , China.
Dianjun Caob Department of Biomedical Sciences and Pathobiology ; Virginia-Maryland College of Veterinary Medicine; Virginia Polytechnic Institute and State University ; Blacksburg , VA USA.
Ronald W Jonesc Rotavirus Vaccine Development Section; Laboratory of Infectious Diseases; National Institute of Allergy and Infectious Diseases; National Institutes of Health ; Bethesda , MD USA.
Yasutaka Hoshinoc Rotavirus Vaccine Development Section; Laboratory of Infectious Diseases; National Institute of Allergy and Infectious Diseases; National Institutes of Health ; Bethesda , MD USA.
Lijuan Yuanb Department of Biomedical Sciences and Pathobiology ; Virginia-Maryland College of Veterinary Medicine; Virginia Polytechnic Institute and State University ; Blacksburg , VA USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The two currently available live oral rotavirus vaccines, Rotarix(®) and RotaTeq(®), are highly efficacious in the developed countries. However, the efficacy of such vaccines in resource deprived countries in Africa and Southeast Asia is low. We reported previously that a bacterially-expressed rotavirus P2-P[8] ΔVP8* subunit vaccine candidate administered intramuscularly elicited high-titers of neutralizing antibodies in guinea pigs and mice and significantly shortened the duration of diarrhea in neonatal gnotobiotic pigs upon oral challenge with virulent human rotavirus Wa strain. To further improve its vaccine potential and provide wider coverage against rotavirus strains of global and regional epidemiologic importance, we constructed 2 tandem recombinant VP8* proteins, P2-P[8] ΔVP8*-P[8] ΔVP8* and P2-P[8] ΔVP8*-P[6] ΔVP8* based on Escherichia coli expression system. The two resulting recombinant tandem proteins were highly soluble and P2-P[8] ΔVP8*-P[8] ΔVP8* was generated with high yield. Moreover, guinea pigs immunized intramuscularly by 3 doses of the P2-P[8] ΔVP8*-P[8] ΔVP8* or P2-P[8] ΔVP8*-P[6] ΔVP8* vaccine with aluminum phosphate adjuvant developed high titers of homotypic and heterotypic neutralizing antibodies against human rotaviruses bearing G1-G4, G8, G9 and G12 with P[8], P[4] or P[6] combination. The results suggest that these 2 subunit vaccines in monovalent or bivalent formulation can provide antigenic coverage to almost all the rotavirus G (VP7) types and major P (VP4) types of global as well as regional epidemiologic importance.

Indexed as

Adjuvants, ImmunologicAluminum CompoundsAnimalsAntibodies, NeutralizingAntibodies, ViralEpitopes, T-LymphocyteEscherichia coliFemaleGene ExpressionGuinea PigsInjections, IntramuscularMutant ProteinsPhosphatesRecombinant ProteinsRNA-Binding ProteinsRotavirus VaccinesAdjuvants, ImmunologicAluminum Compoundsaluminum phosphateAntibodies, NeutralizingAntibodies, ViralEpitopes, T-LymphocyteMutant ProteinsNS35 protein, rotavirusPhosphatesRecombinant ProteinsRNA-Binding ProteinsRotavirus VaccinesVaccines, SubunitVaccines, SyntheticViral Nonstructural ProteinsP typerotavirussubunit vaccineuniversal T cell epitopeVP8* protein

Identifiers

PMID26091081
PMCPMC4635725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.